Engineered tumor cell source microparticle targeting succinic acid as well as preparation method and application of engineered tumor cell source microparticle
By engineering the microparticles of tumor cell-derived origin that target succinic acid, highly express succinic acid receptors and inhibit succinic acid-succinic acid receptor signals, the problem of difficult inhibition of succinic acid-succinic acid receptor axis in the tumor microenvironment is solved. The M1 polarization and tumor treatment effect of tumor-associated macrophages have been achieved, and the efficacy of immunotherapy is enhanced when combined with PD-1 antibodies is enhanced.
Patent Information
- Application Number
- CN202411127162.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-16
AI Technical Summary
The prior art is difficult to effectively inhibit the succinate-succinate receptor axis in the tumor microenvironment, resulting in difficult tumor promotion signals and poor inhibition effect.
Provide a tumor cell-derived microparticle that is engineered to target succinate. It infects succinate receptor genes through lentiviruses, highly expresses succinate receptors, and obtains microparticles loaded on the plasma membrane surface through differential centrifugation, and binds to tumor microparticles. Succinic acid in the environment inhibits succinic-succinic acid receptor signaling and delivers succinic acid into macrophages, inducing M1 polarization.
It has achieved effective inhibition of the succinate-succinate receptor axis in the tumor microenvironment, enhanced the M1 polarization of macrophages, improved the tumor immune microenvironment, significantly inhibited tumor proliferation and migration, and had good therapeutic effects, and combined with The efficacy of immunotherapy is enhanced when combined with PD-1 antibodies.
Smart Images

Figure CN119055790A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to an engineered succinic acid-targeted tumor cell-derived microparticle and a preparation method and application thereof. Background Art
[0002] Succinic acid is a metabolite of the tricarboxylic acid cycle and accumulates in the tumor microenvironment of certain tumors. In addition, succinic acid can also serve as an important signaling molecule, activating its downstream signaling pathway by binding to the succinic acid receptor (a G protein-coupled receptor). The succinic acid receptor is widely distributed in the human body and is expressed in different types of cells such as hepatic stellate cells, kidney and intestinal epithelial cells, macrophages, and monocyte-derived dendritic cells. In the tumor microenvironment, succinic acid receptors are mainly present on the surface of tumor cells and tumor-associated macrophages and play different functions, promoting tumor cell proliferation and migration.
[0003] The succinate receptor signal in macrophages can promote the polarization of tumor-associated macrophages toward the M2 type and further produce a tumor-promoting effect. In general, the succinate-succinate receptor axis plays a role in promoting the occurrence and development of tumors in the tumor microenvironment.
[0004] In the prior art, there are two ways to target the succinate-succinate receptor axis. One is to use blocking antibodies to block the succinate receptor, but the production of blocking antibodies is expensive and takes a long time. The other is to deliver siRNA of the succinate receptor to reduce the expression of the succinate receptor in cells, but the targeting and safety of this approach in vivo are unclear, and both methods can only inhibit the succinate receptor signal to a certain extent, and the inhibitory effect is not good. Summary of the invention
[0005] The purpose of the present invention is to provide an engineered tumor cell-derived microparticle targeting succinic acid and a preparation method and application thereof, so as to solve the technical problem in the prior art that succinic acid is not easily inhibited in the tumor microenvironment.
[0006] In order to solve the above technical problems, the present invention specifically provides the following technical solutions:
[0007] The invention provides an engineered tumor cell-derived microparticle targeting succinic acid, comprising the tumor cell-derived microparticle and a succinic acid receptor loaded on the surface of its plasma membrane.
[0008] As a preferred embodiment of the present invention, in the parent cell, the mRNA expression level of the succinate receptor is more than 5 times the expression level of β-actin.
[0009] As a preferred embodiment of the present invention, the particle size of the tumor cell-derived microparticles is 50-500 nm, preferably 100-300 nm, and more preferably 120-250 nm.
[0010] The present invention also provides a method for preparing engineered succinic acid-targeted tumor cell-derived microparticles, comprising the following steps:
[0011] S100, using lentivirus to infect cells and perform monoclonal screening, selecting cell lines with succinate receptor expression levels more than 5 times that of β-actin to obtain engineered cells;
[0012] S200, inducing apoptosis of the engineered cells and releasing cell-derived microparticles, collecting the supernatant, performing differential centrifugation, and taking the precipitate to obtain the engineered tumor cell-derived microparticles targeting succinic acid.
[0013] As a preferred solution of the present invention, in S100,
[0014] The cells are solid tumor cells;
[0015] The steps of infecting cells were as follows: the multiplicity of infection (MOI) was 10, and the cells were cultured in a constant temperature incubator at 37°C and 5% CO2 for 48 h;
[0016] The cells were suspended in physiological saline and placed at 37°C for 20-30 h; or 2 The cells were irradiated with UV light for 0.5-1.5 h at an irradiation intensity of 1.5.
[0017] As a preferred solution of the present invention, in S100,
[0018] The lentivirus carries a succinic acid overexpression gene;
[0019] The preparation method of the lentivirus is a three-plasmid co-transfection system, and the specific conditions are as follows:
[0020] HEK293T cells were transfected with a plasmid carrying a succinic acid overexpression gene, cultured at 37°C and 5% CO2 for 72 h, and ultracentrifuged to concentrate viral particles before harvesting the viral supernatant;
[0021] The plasmid carrying the succinic acid overexpression gene is a plasmid in which the expression of the succinic acid receptor gene is driven by a strong promoter;
[0022] The plasmid is a cytomegalovirus promoter or an elongation factor 1-α promoter.
[0023] As a preferred embodiment of the present invention, in S200, the step of inducing apoptosis of the engineered cells is as follows: suspending the engineered cells with physiological saline and placing them at 37° C. for 20-30 hours;
[0024] The conditions of the differential centrifugation are as follows: 1000-50000 g gradient centrifugation for 1-1.5 h, temperature is 4°C.
[0025] The present invention also provides the use of engineered succinic acid-targeted tumor cell-derived microparticles in the preparation of drugs for preventing and / or treating cancer.
[0026] As a preferred embodiment of the present invention, the drug comprises engineered tumor cell-derived microparticles targeting succinic acid and a pharmaceutically acceptable carrier.
[0027] As a preferred embodiment of the present invention, the cancer includes liver cancer, bladder cancer, bone cancer, brain cancer, breast cancer, colorectal cancer, endometrial cancer, cervical cancer, esophageal cancer, eye cancer, head and neck cancer, kidney cancer, lung cancer, gallbladder cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, and thyroid cancer.
[0028] As a preferred embodiment of the present invention, the engineered tumor cell-derived microparticles targeting succinic acid are used in combination with PD-1 antibodies to enhance the reactivity of PD-1 antibodies and improve the efficacy of immunotherapy.
[0029] Compared with the prior art, the present invention has the following beneficial effects:
[0030] The microparticles provided by the present invention are endogenous substances of the body. Due to the "homing effect", they can better target tumor tissues. After binding to the succinate receptor, on the one hand, they can well bind to succinate in the tumor microenvironment and inhibit the tumor-promoting effect mediated by succinate. On the other hand, they can achieve the effect of delivering endogenous succinate into macrophages. After being delivered into the macrophages, they can inhibit the succinate-succinate receptor axis in the macrophages, inhibit the M2 polarization signal, increase the level of succinate in the macrophages, induce M1 polarization, improve the tumor immune microenvironment, and have a good therapeutic effect on various individual tumors.
[0031] The preparation method provided by the present invention is simple, and compared with chemically synthesized nanocarriers or other immune drugs, it is safer, has a richer source, is easier to obtain, targets most tumors, has good universality, is easy to produce, and is efficient.
[0032] Compared with unmodified microparticles, the engineered succinic acid-targeted tumor cell-derived microparticles provided by the present invention can be used to prepare drugs for preventing and / or treating various cancers. When used in combination with PD-1 antibodies, the responsiveness of PD-1 antibodies can be enhanced, thereby improving the efficacy of immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.
[0034] Figure 1 A schematic diagram of mass expression of mRNA of succinate receptor is provided for Example 1 of the present invention;
[0035] Figure 2 Provided in Example 1 of the present invention is a diagram showing the cell membrane of an engineered tumor cell being developed by a red fluorescent secondary antibody;
[0036] Figure 3 Provides a particle size diagram of tumor cell-derived microparticles engineered to target succinic acid for Example 1 of the present invention;
[0037] Figure 4 Provides a morphological diagram of tumor cell-derived microparticles engineered to target succinic acid for Example 1 of the present invention;
[0038] Figure 5 A distribution diagram of microparticles with high expression of succinate receptor in the extracted microparticles is provided for Example 1 of the present invention;
[0039] Figure 6 A schematic diagram of the ability of engineered succinic acid-targeted tumor cell-derived microparticles to bind succinic acid in the environment is provided for Example 1 of the present invention;
[0040] Figure 7 A schematic diagram of the situation in which the tumor cell-derived microparticles engineered to target succinic acid reverse the polarization of M2 macrophages is provided for the verification example 1 of the present invention;
[0041] Figure 8 Provided for the verification example 2 of the present invention is a tumor morphology image of a mouse breast cancer 4T1 subcutaneous tumor model after treatment;
[0042] Fig. 9 Provided for the verification example 2 of the present invention, a statistical graph of tumor volume and mouse survival rate after treatment of mouse breast cancer 4T1 subcutaneous tumor model;
[0043] Fig.10 Provided for the verification example 2 of the present invention is a tumor morphology diagram of a mouse breast cancer EMT-6 subcutaneous tumor model after treatment;
[0044] Fig.11 Provided for the verification example 2 of the present invention, a statistical graph of tumor volume and mouse survival rate after treatment of the mouse breast cancer EMT-6 subcutaneous tumor model;
[0045] Fig.12 Provides a statistical graph of ascites volume and mouse survival rate after treatment of a mouse liver cancer ascites model for Verification Example 2 of the present invention;
[0046] Fig.13 Provided for the verification example 3 of the present invention is a tumor morphology image of the tumor cell-derived microparticles targeting succinic acid and enhancing the anti-PD-1 antibody immunotherapy of the 4T1 mouse breast cancer subcutaneous tumor model;
[0047] Fig.14 Provided for Verification Example 3 of the present invention are statistical graphs of tumor volume and mouse survival rate after immunotherapy of 4T1 mouse breast cancer subcutaneous tumor model with engineered succinic acid-targeted tumor cell-derived microparticles enhanced with anti-PD-1 antibodies. DETAILED DESCRIPTION
[0048] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0049] The invention provides an engineered tumor cell-derived microparticle targeting succinic acid, comprising the tumor cell-derived microparticle and a succinic acid receptor loaded on the surface of its plasma membrane.
[0050] Microparticles are a type of extracellular vesicles, produced by cell membrane budding, and the particle size is mainly distributed in 50-500nm. According to the report of Reference 2, tumor-derived microparticles can induce tumor immune response. In addition, microparticles are extremely excellent engineered carriers, and their safety, circulation stability, and targeting have been verified in many studies and clinical trials. In the present invention, "cell microparticles", "cell-derived microparticles", "cell-derived microparticles" and "cell-derived microparticles" are universal, referring to cell vesicles produced by apoptosis, which have not been engineered.
[0051] Microparticles can be derived from solid tumor cells, immune cells, stem cells. Solid tumor cells include, but are not limited to, tumor cells in breast cancer, liver cancer, bladder cancer, bone cancer, brain cancer, colorectal cancer, endometrial cancer, cervical cancer, esophageal cancer, eye cancer, head and neck cancer, kidney cancer, lung cancer, gallbladder cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, thyroid cancer, etc. Immune cells include T cells, B cells, natural killer cells, macrophages, dendritic cells, mast cells, neutrophils, natural immune cells. Stem cells include embryonic stem cells, induced pluripotent stem cells, adult stem cells, and tissue-specific stem cells.
[0052] In the present invention, "succinate receptor" refers to a G protein-coupled receptor, also known as GPR91 or SUCNR1.
[0053] The engineered tumor cell-derived microparticles targeting succinic acid are obtained by "engineering" tumor cell-derived microparticles, which means that the succinic acid receptor gene is introduced into the receptor cells by lentiviral infection, and the succinic acid receptor protein is expressed on the surface of the receptor cell membrane, that is, the engineered tumor cell-derived microparticles targeting succinic acid.
[0054] Microparticles are endogenous substances of the body. Compared with chemically synthesized nanocarriers or other immune drugs, they are safer, more abundant in source, and easier to obtain. Microparticles derived from tumor cells can better target tumor tissues due to the "homing effect". On this basis, using them as engineered carriers can achieve targeting of tumor tissues. Selecting appropriate parent cells can target most tumors, which has good universality.
[0055] In a preferred embodiment of the present invention, succinate receptors are highly expressed in the above-mentioned engineered succinate-targeted tumor cell-derived microparticles.
[0056] The effects of extracellular succinate and intracellular succinate may be completely opposite. Studies have shown that the metabolic pattern of M1 macrophages changes, and the level of succinate in their cytoplasm increases significantly. When exogenous succinate is delivered into macrophages using succinate-loaded tumor cell-derived microparticles, the level of succinate in their cytoplasm and nucleus increases, and certain proteins undergo succinylation, which can lead to the induction of macrophages into the M1 phenotype.
[0057] In the present invention, in particular, the cell-derived microparticles with high expression of succinate receptors provided by the present invention can bind to succinate in the tumor microenvironment and deliver it to macrophages.
[0058] Delivery of exogenous succinic acid may increase the level of succinic acid in the tumor microenvironment and activate the tumor-promoting signals mediated by succinic acid receptors. Therefore, the present invention directly targets endogenous succinic acid in the tumor microenvironment and delivers it into macrophages, which can simultaneously inhibit succinic acid receptor signals and mediate M1 polarization induced by intracellular protein succinylation, thereby directly inhibiting tumor proliferation and migration while improving the tumor immune microenvironment, which is a promising new immunotherapy strategy.
[0059] The present invention can produce the following three effects: 1. Reduce the level of succinic acid in the tumor microenvironment, inhibit the tumor proliferation and migration signals mediated by the succinic acid-succinic acid receptor axis in tumor cells; 2. Inhibit the succinic acid-succinic acid receptor axis in macrophages, inhibit the tumor-promoting M2 polarization signal; 3. Increase the level of succinic acid in macrophages, and induce anti-tumor M1 polarization.
[0060] The phenotype and function of macrophages are not simply a binary opposition between M1 and M2, but are often in a dynamic state of change and are regulated by the environment in which they are located. In the tumor microenvironment, tumor-associated macrophages mainly exist with a phenotype that is biased towards M2 due to the influence of multiple signals including succinate receptor signals. M2-like tumor-associated macrophages can secrete cytokines such as IL-10, TGF-β, and VEGF to promote the occurrence and development of tumors. Tumor cell-derived microparticles engineered to target succinate can bind to succinate in the tumor microenvironment, resulting in a decrease in the relative level of succinate without activating succinate receptor signals on tumor cells or macrophages.
[0061] In addition, since macrophages have a strong phagocytic effect on microparticles, in the process of phagocytizing microparticles, macrophages also ingest a large amount of succinic acid bound to the surface of tumor cell-derived microparticles engineered to target succinic acid, resulting in an increase in the level of succinic acid in macrophages, which then induces M1 polarization through succinylation of certain proteins and epigenetic modification. M1-like tumor-associated macrophages can secrete cytokines such as TNF-α, IL-12, and IL-1β to enhance anti-tumor immune response. At the same time, M1-like tumor-associated macrophages can present tumor antigens to CD4+T cells through upregulated MHC class II molecules, further promoting the activation and effect of CD8+T cells.
[0062] It can be seen that the use of engineered succinate-targeted tumor cell-derived microparticles to bind succinate in the tumor microenvironment can achieve two effects. One is to inhibit the succinate-succinate receptor signaling of various cells in the tumor microenvironment (mainly tumor cells and macrophages); the other is to deliver succinate into macrophages to achieve M1 polarization of macrophages (this process involves protein succinylation and epigenetic modification). The effect is far greater than directly blocking succinate receptors, so targeting succinate is a better choice.
[0063] Compared with unmodified microparticles, the engineered succinic acid-targeted tumor cell-derived microparticles provided by the present invention can reverse the polarization of tumor-associated macrophages, and have obvious therapeutic effects on a variety of mouse subcutaneous tumors and mouse tumor ascites models, thereby improving the survival of mice.
[0064] In addition, its combined use with PD-1 antibodies can enhance the responsiveness of PD-1 antibodies and improve the efficacy of immunotherapy.
[0065] In the present invention, the particle size of the cell-derived microparticles is 50-500 nm, preferably 100-300 nm, and more preferably 120-250 nm.
[0066] In the parental cells, the mRNA expression level of the succinate receptor is more than 5 times that of β-actin, thereby being able to more strongly reduce the level of succinate in the tumor microenvironment and inhibit the succinate-succinate receptor axis in tumor cells.
[0067] The present invention provides a method for preparing engineered succinic acid-targeted tumor cell-derived microparticles, which specifically comprises the following steps:
[0068] S100, using lentivirus to infect cells and perform monoclonal screening, selecting cell lines with succinate receptor expression levels more than 5 times that of β-actin to obtain engineered cells;
[0069] S200, inducing apoptosis of the engineered cells and releasing cell-derived microparticles, collecting the supernatant, performing differential centrifugation, and taking the precipitate to obtain the engineered tumor cell-derived microparticles targeting succinic acid.
[0070] The preparation method of the invention can efficiently prepare engineered tumor cell-derived microparticles targeting succinic acid.
[0071] In a preferred embodiment, the method for preparing tumor cells that highly express succinate receptors uses lentiviral infection technology, preferably adding polybrene to enhance transfection efficiency, and the specific operating conditions are set as follows: the multiplicity of infection (MOI) is 10, and cultured in a constant temperature incubator at 37°C and 5% CO2 for 48 hours to ensure that the virus particles fully infect the tumor cells and achieve efficient expression of the succinate receptors.
[0072] In a preferred embodiment, the preparation method of the lentivirus carrying the succinate overexpression gene is to use a three-plasmid co-transfection system, preferably a calcium phosphate transfection method or a liposome transfection method, and the specific conditions are: transfection is performed in HEK293T cells, and after transfection, the cells are cultured at 37° C. and 5% CO2 for 72 hours, and ultracentrifugation is preferably performed before harvesting the viral supernatant to concentrate the viral particles.
[0073] In a preferred embodiment, the plasmid carrying the succinate overexpression gene is a plasmid in which the expression of the succinate receptor gene is driven by a strong promoter, preferably a CMV (cytomegalovirus) promoter or an EF1-α (elongation factor 1-α) promoter.
[0074] In a preferred embodiment, the tumor cell is a solid tumor cell. In some preferred embodiments, the solid tumor cell includes but is not limited to tumor cells in breast cancer, liver cancer, bladder cancer, bone cancer, brain cancer, colorectal cancer, endometrial cancer, cervical cancer, esophageal cancer, eye cancer, head and neck cancer, kidney cancer, lung cancer, gallbladder cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, thyroid cancer, etc. In some specific embodiments, the tumor cell is a breast cancer cell.
[0075] The method for inducing tumor cell apoptosis is starvation treatment, preferably using physiological saline to starve the tumor cells, and the specific conditions are: suspending the tumor cells with physiological saline and placing them at 37° C. for 20-30 hours, preferably 24 hours.
[0076] In a preferred embodiment, the number of tumor cells induced to apoptosis is 1×10 7 -1×10 8 1×10 10 -1×10 11 The cell-derived microparticles.
[0077] In a preferred embodiment, after inducing tumor cell apoptosis to release cell-derived microparticles, the microparticles are collected. The specific collection method can be: collecting the cell suspension, centrifuging at 500-1000g for 3-7min, preferably at 800g for 5min, collecting the supernatant, and gradient centrifuging the supernatant at 1000-50000g for 1-1.5h. The visible precipitate is the cell-derived microparticles.
[0078] In a preferred embodiment, the centrifugation conditions are: centrifugation at 1000-50000 g for 1-1.5 h, preferably centrifugation at 14000 g for 1 h, preferably centrifugation in a low temperature environment (4° C.).
[0079] In a preferred embodiment, the centrifugation conditions are: centrifugation at 1000-50000 g for 1-1.5 h, preferably centrifugation at 14000 g for 1 h, preferably centrifugation in a low temperature environment (4° C.).
[0080] The ability of the engineered succinate-targeted tumor cell-derived microparticles to bind succinate in the environment was 1×10 10 Each microparticle can bind 0.01-10 μmol succinic acid.
[0081] The present invention also discloses the use of engineered succinic acid-targeted tumor cell-derived microparticles in the preparation of drugs for preventing and / or treating cancer.
[0082] The drug comprises the engineered succinic acid-targeted tumor cell-derived microparticles prepared by the above preparation method and a pharmaceutically acceptable carrier.
[0083] Preferably, the cancer includes breast cancer, liver cancer, bladder cancer, bone cancer, brain cancer, colorectal cancer, endometrial cancer, cervical cancer, esophageal cancer, eye cancer, head and neck cancer, kidney cancer, lung cancer, gallbladder cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, thyroid cancer; more preferably, the cancer is breast cancer, liver cancer and colorectal cancer.
[0084] The present invention provides a method for preventing and / or treating cancer, which comprises administering an effective amount of the engineered succinic acid-targeted tumor cell-derived microparticles to an individual in need thereof; preferably, the cancer comprises breast cancer, liver cancer, bladder cancer, bone cancer, brain cancer, colorectal cancer, endometrial cancer, cervical cancer, esophageal cancer, eye cancer, head and neck cancer, kidney cancer, lung cancer, gallbladder cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, thyroid cancer; more preferably, the cancer is breast cancer, liver cancer and colorectal cancer.
[0085] The above-mentioned engineered tumor cell-derived microparticles targeting succinic acid are further described below through examples.
[0086] Embodiment 1:
[0087] 1. Preparation of engineered tumor cell-derived microparticles targeting succinate
[0088] Collect 1x10 6 Wild-type or overexpressing succinate receptor tumor cells were used to extract total RNA using Qiagen RNeasy MiniKit according to the manufacturer's instructions. 1 μg of total RNA was reverse transcribed into cDNA using reverse transcriptase. Real-time fluorescence quantitative PCR reactions were performed using specific succinate receptor gene primers and internal reference gene β-actin primers.
[0089] The target gene Ct was compared with its own internal reference Ct value to calculate the expression of succinate receptor relative to the internal reference gene β-actin. 4 Wild-type or overexpressed succinate receptor tumor cells were seeded into confocal dishes, incubated for 24 hours, supernatant discarded, fixed with paraformaldehyde for 30 minutes, then washed three times with PBS; then succinate receptor antibody (NOVUS, NBP1-00861, 1:100) was used, incubated at 4°C in the dark for 8 hours, then washed three times with PBS; CY3 goat anti-rabbit fluorescent secondary antibody (1:100) was added, incubated at 4°C in the dark for 1 hour. DAPI was used to label the cell nucleus (1:1000), washed three times with PBS, and then detected with laser confocal microscopy.
[0090] Figure 1This is the cell line with the highest expression of succinate receptor selected from twenty monoclonal cell lines. Compared with the wild-type EMT-6, its succinate receptor mRNA is expressed in large quantities.
[0091] Figure 2 The cell membrane of the engineered tumor cells was visualized by red fluorescent secondary antibody, showing that a large number of succinate receptors were expressed on the cell membrane.
[0092] The results are as follows Figure 1 and Figure 2 As shown, succinate receptor is abundantly expressed in the engineered cells.
[0093] 2. Characterization: particle size, electron microscopy
[0094] Collect 1×10 8 After each tumor cell was resuspended in physiological saline, it was plated into a 15 cm cell culture dish and placed in a 37°C cell culture incubator for 24 h. The cells were collected and centrifuged at 800 g for 5 min. The supernatant was collected and centrifuged at 14,000 g for 2 min to remove cell debris. The supernatant was then centrifuged at 14,000 g for 1 h to collect tumor cell microparticles. The supernatant was discarded and the microparticles (visible precipitate) were resuspended in PBS and stored at 4°C.
[0095] The particle size of the microparticles was detected by nanoparticle tracking analysis (NTA), and the morphology of the microparticles was detected by electron microscopy.
[0096] The results are as follows Figure 3 to Figure 4 Shown are the particle size and morphology of cell-derived microparticles.
[0097] Figure 3 This is the particle size of cell-derived microparticles detected by a nanoparticle tracker. It can be seen that the particle size distribution of cell-derived microparticles is relatively uniform, concentrated around 200 nm.
[0098] Figure 4 It is a morphological display of cell-derived microparticles observed by scanning electron microscopy.
[0099] 3. Detection of receptor expression
[0100] Take 1×10 8 The engineered tumor cell-derived microparticles targeting succinate were diluted to 100ul with PBS, incubated with 1ul succinate receptor antibody (NOVUS, NBP1-00861, 1:100) at 4°C for 8h, centrifuged at 14000g for 30min, and washed 3 times.
[0101] Then, the cells were incubated with FITC goat anti-rabbit fluorescent secondary antibody (Abcam, ab6717, 1:100) and CD9 antibody (Abcam, ab82392, 1:100) at 4°C for 30 min, washed three times with PBS, diluted to an appropriate concentration, and detected using a nanoflow cytometer (Nanofcm U30E).
[0102] The results are as follows Figure 5 As shown, nearly 90% of the microparticles were double positive for succinate receptor and CD9, demonstrating the ubiquitous expression of succinate receptor on engineered microparticles, and their particle size distribution was consistent with the results of nanoparticle tracking.
[0103] 4. Detection of the binding capacity of succinic acid in the environment
[0104] In 1 ml of 2 mM succinic acid solution, 1 × 10 8 , 5×10 8 , 1×10 9 , 5×10 9 , 1×10 10 , 5×10 10 , 1×10 11 The engineered tumor cell-derived microparticles targeting succinic acid prepared in step 1 were placed at room temperature for 10 minutes and then centrifuged at 14000g for 30 minutes. 100% methanol water was added to the supernatant to dilute the methanol to 80%, and the precipitate was lysed with 80% methanol water, and then the succinic acid level in the sample was analyzed by liquid chromatography-tandem mass spectrometry.
[0105] The results are as follows Figure 6 As shown, tumor cell-derived microparticles engineered to target succinate can bind succinate in the environment and reduce the concentration of succinate in the solution.
[0106] Example 1 illustrates that according to the method disclosed in the present invention, engineered tumor cell-derived microparticles targeting succinic acid are prepared, succinic acid receptors are ubiquitously expressed on the engineered microparticles, and can bind to succinic acid in the environment to reduce the concentration of succinic acid in the solution.
[0107] The functions of the engineered succinate-targeted tumor cell-derived microparticles are verified through multiple verification examples.
[0108] Verification Example 1: Reversal of M2 macrophage polarization
[0109] Mouse bone marrow primary cells were obtained, and the femur and tibia were separated from C57BL / 6J mice. The bone marrow cells were rinsed out with PBS, and red blood cell lysis buffer was added and allowed to stand for 3 minutes. After neutralization with the culture medium, the cells were centrifuged at 400g for 5 minutes. The cell pellets were resuspended and plated into 6-well plates. The cells were cultured with DMEM culture medium containing 20ng / ml M-CSF on the third day.
[0110] On the 5th day, 20ng / ml IL-4 was added to the culture medium, and after 24h of treatment, the cells became M2 bone marrow-derived macrophages.
[0111] Physiological saline, succinic acid, unmodified microparticles, microparticles derived from tumor cells engineered to target succinic acid, succinic acid + unmodified microparticles, and succinic acid + microparticles derived from tumor cells engineered to target succinic acid were added to each well of M2 macrophages. After 12 hours, the cells were collected and total RNA was extracted. After reverse transcription, real-time fluorescence quantitative PCR was performed to calculate the relative expression levels of NOS2 and Arg1.
[0112] The results are as follows Figure 7 As shown, the expression of NOS2 in the succinate+engineered succinate-targeted tumor cell-derived microparticles group increased significantly, while the expression of Arg1 was significantly downregulated. This indicates that the engineered succinate-targeted tumor cell-derived microparticles can reverse the polarization of M2 macrophages in the presence of succinate and induce them to be similar to M1.
[0113] It can be seen from Verification Example 1 that the engineered succinic acid-targeted tumor cell-derived microparticles prepared in Example 1 can reverse the polarization of tumor-associated macrophages.
[0114] Verification Example 2: There is a significant therapeutic effect on various mouse subcutaneous tumor and mouse tumor ascites models
[0115] BALB / c mice were subcutaneously inoculated with 1×10 5 BALB / c mice were intraperitoneally injected with 1×10 4T1 or EMT-6 mouse breast cancer cells. 5 H22 mouse liver cancer cells. One week later, treatment was started every two days for two weeks. Microparticles were injected intravenously in the subcutaneous tumor model and intraperitoneally in the ascites model.
[0116] The mice were divided into three treatment groups, with 6 mice in each group. The treatment methods were the same within each group: blank control group Con (100ul normal saline), unmodified microparticle group NC-MP (1x10 11 ), the engineered succinic acid-targeted tumor cell-derived microparticle group eSRhe-MP (1x10 11 indivual).
[0117] The subcutaneous tumors of mice were observed and their volumes were measured.
[0118] The results are as follows Figures 8 to 12 As shown, it shows the therapeutic effect of tumor cell microparticles engineered to highly express succinate receptors on a mouse tumor model.
[0119] Figure 8 , 9 , 10, 11 and 12 showed that after treatment, the tumor volume of mouse breast cancer 4T1 and EMT-6 subcutaneous tumor models was reduced and the survival period was prolonged.
[0120] Figures 8 to 12 It showed that the ascites volume of the mouse liver cancer ascites model was reduced after treatment and the survival time of the mice was prolonged after treatment.
[0121] It can be seen from Verification Example 2 that the results obtained in Example 1 indicate that the engineered tumor cell microparticles with high expression of succinate receptors have a good therapeutic effect on mouse breast cancer models and mouse liver cancer models, and improve the survival of mice.
[0122] Verification Example 3: Enhanced reactivity of PD-1 antibody after combination with PD-1 antibody
[0123] BALB / c mice were subcutaneously inoculated with 1×10 5 One week later, physiological saline, unengineered microparticles, and microparticles derived from tumor cells targeting succinic acid in Example 1 were injected into the tail vein every 2 days, and PD-1 antibody was injected into the tail vein every 4 days for two weeks.
[0124] The mice were divided into five treatment groups, 8 in each group, and the treatment methods were the same within each group: blank control group Con (100ul saline), unmodified microparticle group NC-MP (1x10 11 ), the engineered succinate-targeted tumor cell-derived microparticle group eSRhe-MP (1x10 11 The subcutaneous tumors of mice were observed and their volumes were measured.
[0125] The results are as follows Figure 13 to Figure 14 As shown, the therapeutic effect of PD-1 antibody combined with tumor cell microparticles engineered to highly express succinate receptors on a mouse tumor model is shown.
[0126] It can be seen from Verification Example 3 that the combined use of the engineered succinic acid-targeted tumor cell-derived microparticles prepared in Example 1 and PD-1 antibodies can enhance the reactivity of PD-1 antibodies and improve the efficacy of immunotherapy.
[0127] Through the engineered succinate-targeted tumor cell-derived microparticles of this embodiment and their preparation method and application, the succinate-succinate receptor signals of various cells in the tumor microenvironment can be inhibited, and endogenous succinate can be delivered into macrophages to achieve the reversal of tumor-associated macrophage polarization, which has a significant therapeutic effect on tumors. When used in combination with PD-1 antibodies, the reactivity of PD-1 antibodies can be enhanced, thereby improving the efficacy of immunotherapy.
[0128] The above embodiments are only exemplary embodiments of the present application and are not intended to limit the present application. The protection scope of the present application is defined by the claims. Those skilled in the art may make various modifications or equivalent substitutions to the present application within the essence and protection scope of the present application, and such modifications or equivalent substitutions shall also be deemed to fall within the protection scope of the present application.
Claims
1. An engineered tumor cell-derived microparticle targeting succinic acid, characterized in that: It includes tumor cell-derived microparticles and succinate receptors loaded on the surface of their plasma membrane.
2. The engineered tumor cell-derived microparticles targeting succinic acid according to claim 1, characterized in that: In the parental cells, the mRNA expression level of the succinate receptor is more than 5 times that of β-actin.
3. The engineered tumor cell-derived microparticles targeting succinic acid according to claim 1, characterized in that: The particle size of the tumor cell-derived microparticles is 120-250 nm.
4. A method for preparing the engineered succinic acid-targeted tumor cell-derived microparticles according to any one of claims 1 to 3, characterized in that: The steps include: S100, using lentivirus to infect cells and perform monoclonal screening, selecting cell lines with succinate receptor expression levels more than 5 times that of β-actin to obtain engineered cells; S200, inducing apoptosis of the engineered cells and releasing cell-derived microparticles, collecting the supernatant, performing differential centrifugation, and taking the precipitate to obtain the engineered tumor cell-derived microparticles targeting succinic acid.
5. The method for preparing an engineered succinic acid-targeted tumor cell-derived microparticle according to claim 4, characterized in that: In S100, The cells are solid tumor cells; The steps of infecting cells were as follows: the multiplicity of infection (MOI) was 10, and the cells were cultured in a constant temperature incubator at 37°C and 5% CO2 for 48 h; The cells were suspended in physiological saline and placed at 37°C for 20-30 h; or 2 The cells were irradiated with UV light for 0.5-1.5 h at an irradiation intensity of 1.
5.
6. The method for preparing an engineered succinic acid-targeted tumor cell-derived microparticle according to claim 4, characterized in that: In S100, The lentivirus carries a succinic acid overexpression gene; The preparation method of the lentivirus is a three-plasmid co-transfection system, and the specific conditions are as follows: HEK293T cells were transfected with a plasmid carrying a succinic acid overexpression gene, cultured at 37°C and 5% CO2 for 72 h, and ultracentrifuged to concentrate viral particles before harvesting the viral supernatant; The plasmid carrying the succinic acid overexpression gene is a plasmid in which the expression of the succinic acid receptor gene is driven by a strong promoter; The plasmid is a cytomegalovirus promoter or an elongation factor 1-α promoter.
7. The method for preparing an engineered tumor cell-derived microparticle targeting succinic acid according to claim 4, characterized in that: In S200, the step of inducing apoptosis of the engineered cells is as follows: suspending the engineered cells with physiological saline and placing them at 37° C. for 20-30 hours; The conditions of the differential centrifugation are as follows: 1000-50000 g gradient centrifugation for 1-1.5 h, temperature is 4°C.
8. Use of the engineered succinic acid-targeted tumor cell-derived microparticles according to any one of claims 1 to 7 in the preparation of a drug for preventing and / or treating cancer.
9. The use of an engineered succinic acid-targeted tumor cell-derived microparticle according to claim 8, characterized in that: The drug comprises engineered succinic acid-targeted tumor cell-derived microparticles prepared by the preparation methods of claims 4 to 6 and a pharmaceutically acceptable carrier.
10. The use of an engineered succinic acid-targeted tumor cell-derived microparticle according to claim 8, characterized in that: The cancers include liver cancer, bladder cancer, bone cancer, brain cancer, breast cancer, colorectal cancer, endometrial cancer, cervical cancer, esophageal cancer, eye cancer, head and neck cancer, kidney cancer, lung cancer, gallbladder cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, stomach cancer, and thyroid cancer.
Citation Information
Patent Citations
Preparation method and application of anti-tumor microparticles modified by genetic engineering
CN111420031A
Use of succinic acid as biomarker for cancer diagnosis and treatment
CN114929274A
Tumor cell source microparticle loaded with succinic acid as well as preparation method and application of tumor cell source microparticle
CN116919918A
Succinate-binding polypeptides and use thereof
US20200262889A1
Tumor cell-derived microparticle loaded with succinic acid, preparation method therefor, and use thereof
WO2023197901A1
